NewAmsterdam Pharma Company (NAMS) has provided an announcement.
NewAmsterdam Pharma Company N.V. reported positive outcomes from its Phase 3 BROOKLYN clinical trial for the drug obicetrapib, which significantly reduced LDL-C levels in patients with familial hypercholesterolemia on lipid-lowering therapy. The sustained benefits over a year, alongside safety results comparable to placebo, set the stage for an upcoming presentation at a medical conference and publication in a medical journal. The company’s forward-looking statements emphasize its strategic plans, regulatory milestones, and commercialization efforts for obicetrapib.
For an in-depth examination of NAMS stock, go to TipRanks’ Stock Analysis page.
